Cargando…

Chemical traits of cerebral amyloid angiopathy in familial British‐, Danish‐, and non‐Alzheimerʼs dementias

Familial British dementia (FBD) and familial Danish dementia (FDD) are autosomal dominant forms of dementia caused by mutations in the integral membrane protein 2B (ITM2B, also known as BRI2) gene. Secretase processing of mutant BRI2 leads to secretion and deposition of BRI2‐derived amyloidogenic pe...

Descripción completa

Detalles Bibliográficos
Autores principales: Michno, Wojciech, Koutarapu, Srinivas, Camacho, Rafael, Toomey, Christina, Stringer, Katie, Minta, Karolina, Ge, Junyue, Jha, Durga, Fernandez‐Rodriguez, Julia, Brinkmalm, Gunnar, Zetterberg, Henrik, Blennow, Kaj, Ryan, Natalie S., Lashley, Tammaryn, Hanrieder, Jörg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828067/
https://www.ncbi.nlm.nih.gov/pubmed/36102248
http://dx.doi.org/10.1111/jnc.15694
_version_ 1784867187108872192
author Michno, Wojciech
Koutarapu, Srinivas
Camacho, Rafael
Toomey, Christina
Stringer, Katie
Minta, Karolina
Ge, Junyue
Jha, Durga
Fernandez‐Rodriguez, Julia
Brinkmalm, Gunnar
Zetterberg, Henrik
Blennow, Kaj
Ryan, Natalie S.
Lashley, Tammaryn
Hanrieder, Jörg
author_facet Michno, Wojciech
Koutarapu, Srinivas
Camacho, Rafael
Toomey, Christina
Stringer, Katie
Minta, Karolina
Ge, Junyue
Jha, Durga
Fernandez‐Rodriguez, Julia
Brinkmalm, Gunnar
Zetterberg, Henrik
Blennow, Kaj
Ryan, Natalie S.
Lashley, Tammaryn
Hanrieder, Jörg
author_sort Michno, Wojciech
collection PubMed
description Familial British dementia (FBD) and familial Danish dementia (FDD) are autosomal dominant forms of dementia caused by mutations in the integral membrane protein 2B (ITM2B, also known as BRI2) gene. Secretase processing of mutant BRI2 leads to secretion and deposition of BRI2‐derived amyloidogenic peptides, ABri and ADan that resemble APP/β‐amyloid (Aβ) pathology, which is characteristic of Alzheimer's disease (AD). Amyloid pathology in FBD/FDD manifests itself predominantly in the microvasculature by ABri/ADan containing cerebral amyloid angiopathy (CAA). While ABri and ADan peptide sequences differ only in a few C‐terminal amino acids, CAA in FDD is characterized by co‐aggregation of ADan with Aβ, while in contrast no Aβ deposition is observed in FBD. The fact that FDD patients display an earlier and more severe disease onset than FBD suggests a potential role of ADan and Aβ co‐aggregation that promotes a more rapid disease progression in FDD compared to FBD. It is therefore critical to delineate the chemical signatures of amyloid aggregation in these two vascular dementias. This in turn will increase the knowledge on the pathophysiology of these diseases and the pathogenic role of heterogenous amyloid peptide interactions and deposition, respectively. Herein, we used matrix‐assisted laser desorption/ionization mass spectrometry imaging (MALDI‐MSI) in combination with hyperspectral, confocal microscopy based on luminescent conjugated oligothiophene probes (LCO) to delineate the structural traits and associated amyloid peptide patterns of single CAA in postmortem brain tissue of patients with FBD, FDD as well as sporadic CAA without AD (CAA+) that show pronounced CAA without parenchymal plaques. The results show that CAA in both FBD and FDD consist of N‐terminally truncated‐ and pyroglutamate‐modified amyloid peptide species (ADan and ABri), but that ADan peptides in FDD are also extensively C‐terminally truncated as compared to ABri in FBD, which contributes to hydrophobicity of ADan species. Further, CAA in FDD showed co‐deposition with Aβ x‐42 and Aβ x‐40 species. CAA+ vessels were structurally more mature than FDD/FBD CAA and contained significant amounts of pyroglutamated Aβ. When compared with FDD, Aβ in CAA+ showed more C‐terminal and less N‐terminally truncations. In FDD, ADan showed spatial co‐localization with Aβ3pE‐40 and Aβ3‐40 but not with Aβx‐42 species. This suggests an increased aggregation propensity of Aβ in FDD that promotes co‐aggregation of both Aβ and ADan. Further, CAA maturity appears to be mainly governed by Aβ content based on the significantly higher 500/580 patterns observed in CAA+ than in FDD and FBD, respectively. Together this is the first study of its kind on comprehensive delineation of Bri2 and APP‐derived amyloid peptides in single vascular plaques in both FDD/FBD and sporadic CAA that provides new insight in non‐AD‐related vascular amyloid pathology.[Image: see text] Cover Image for this issue: https://doi.org/10.1111/jnc.15424
format Online
Article
Text
id pubmed-9828067
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-98280672023-01-10 Chemical traits of cerebral amyloid angiopathy in familial British‐, Danish‐, and non‐Alzheimerʼs dementias Michno, Wojciech Koutarapu, Srinivas Camacho, Rafael Toomey, Christina Stringer, Katie Minta, Karolina Ge, Junyue Jha, Durga Fernandez‐Rodriguez, Julia Brinkmalm, Gunnar Zetterberg, Henrik Blennow, Kaj Ryan, Natalie S. Lashley, Tammaryn Hanrieder, Jörg J Neurochem ORIGINAL ARTICLES Familial British dementia (FBD) and familial Danish dementia (FDD) are autosomal dominant forms of dementia caused by mutations in the integral membrane protein 2B (ITM2B, also known as BRI2) gene. Secretase processing of mutant BRI2 leads to secretion and deposition of BRI2‐derived amyloidogenic peptides, ABri and ADan that resemble APP/β‐amyloid (Aβ) pathology, which is characteristic of Alzheimer's disease (AD). Amyloid pathology in FBD/FDD manifests itself predominantly in the microvasculature by ABri/ADan containing cerebral amyloid angiopathy (CAA). While ABri and ADan peptide sequences differ only in a few C‐terminal amino acids, CAA in FDD is characterized by co‐aggregation of ADan with Aβ, while in contrast no Aβ deposition is observed in FBD. The fact that FDD patients display an earlier and more severe disease onset than FBD suggests a potential role of ADan and Aβ co‐aggregation that promotes a more rapid disease progression in FDD compared to FBD. It is therefore critical to delineate the chemical signatures of amyloid aggregation in these two vascular dementias. This in turn will increase the knowledge on the pathophysiology of these diseases and the pathogenic role of heterogenous amyloid peptide interactions and deposition, respectively. Herein, we used matrix‐assisted laser desorption/ionization mass spectrometry imaging (MALDI‐MSI) in combination with hyperspectral, confocal microscopy based on luminescent conjugated oligothiophene probes (LCO) to delineate the structural traits and associated amyloid peptide patterns of single CAA in postmortem brain tissue of patients with FBD, FDD as well as sporadic CAA without AD (CAA+) that show pronounced CAA without parenchymal plaques. The results show that CAA in both FBD and FDD consist of N‐terminally truncated‐ and pyroglutamate‐modified amyloid peptide species (ADan and ABri), but that ADan peptides in FDD are also extensively C‐terminally truncated as compared to ABri in FBD, which contributes to hydrophobicity of ADan species. Further, CAA in FDD showed co‐deposition with Aβ x‐42 and Aβ x‐40 species. CAA+ vessels were structurally more mature than FDD/FBD CAA and contained significant amounts of pyroglutamated Aβ. When compared with FDD, Aβ in CAA+ showed more C‐terminal and less N‐terminally truncations. In FDD, ADan showed spatial co‐localization with Aβ3pE‐40 and Aβ3‐40 but not with Aβx‐42 species. This suggests an increased aggregation propensity of Aβ in FDD that promotes co‐aggregation of both Aβ and ADan. Further, CAA maturity appears to be mainly governed by Aβ content based on the significantly higher 500/580 patterns observed in CAA+ than in FDD and FBD, respectively. Together this is the first study of its kind on comprehensive delineation of Bri2 and APP‐derived amyloid peptides in single vascular plaques in both FDD/FBD and sporadic CAA that provides new insight in non‐AD‐related vascular amyloid pathology.[Image: see text] Cover Image for this issue: https://doi.org/10.1111/jnc.15424 John Wiley and Sons Inc. 2022-09-25 2022-11 /pmc/articles/PMC9828067/ /pubmed/36102248 http://dx.doi.org/10.1111/jnc.15694 Text en © 2022 The Authors. Journal of Neurochemistry published by John Wiley & Sons Ltd on behalf of International Society for Neurochemistry. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle ORIGINAL ARTICLES
Michno, Wojciech
Koutarapu, Srinivas
Camacho, Rafael
Toomey, Christina
Stringer, Katie
Minta, Karolina
Ge, Junyue
Jha, Durga
Fernandez‐Rodriguez, Julia
Brinkmalm, Gunnar
Zetterberg, Henrik
Blennow, Kaj
Ryan, Natalie S.
Lashley, Tammaryn
Hanrieder, Jörg
Chemical traits of cerebral amyloid angiopathy in familial British‐, Danish‐, and non‐Alzheimerʼs dementias
title Chemical traits of cerebral amyloid angiopathy in familial British‐, Danish‐, and non‐Alzheimerʼs dementias
title_full Chemical traits of cerebral amyloid angiopathy in familial British‐, Danish‐, and non‐Alzheimerʼs dementias
title_fullStr Chemical traits of cerebral amyloid angiopathy in familial British‐, Danish‐, and non‐Alzheimerʼs dementias
title_full_unstemmed Chemical traits of cerebral amyloid angiopathy in familial British‐, Danish‐, and non‐Alzheimerʼs dementias
title_short Chemical traits of cerebral amyloid angiopathy in familial British‐, Danish‐, and non‐Alzheimerʼs dementias
title_sort chemical traits of cerebral amyloid angiopathy in familial british‐, danish‐, and non‐alzheimerʼs dementias
topic ORIGINAL ARTICLES
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828067/
https://www.ncbi.nlm.nih.gov/pubmed/36102248
http://dx.doi.org/10.1111/jnc.15694
work_keys_str_mv AT michnowojciech chemicaltraitsofcerebralamyloidangiopathyinfamilialbritishdanishandnonalzheimerʼsdementias
AT koutarapusrinivas chemicaltraitsofcerebralamyloidangiopathyinfamilialbritishdanishandnonalzheimerʼsdementias
AT camachorafael chemicaltraitsofcerebralamyloidangiopathyinfamilialbritishdanishandnonalzheimerʼsdementias
AT toomeychristina chemicaltraitsofcerebralamyloidangiopathyinfamilialbritishdanishandnonalzheimerʼsdementias
AT stringerkatie chemicaltraitsofcerebralamyloidangiopathyinfamilialbritishdanishandnonalzheimerʼsdementias
AT mintakarolina chemicaltraitsofcerebralamyloidangiopathyinfamilialbritishdanishandnonalzheimerʼsdementias
AT gejunyue chemicaltraitsofcerebralamyloidangiopathyinfamilialbritishdanishandnonalzheimerʼsdementias
AT jhadurga chemicaltraitsofcerebralamyloidangiopathyinfamilialbritishdanishandnonalzheimerʼsdementias
AT fernandezrodriguezjulia chemicaltraitsofcerebralamyloidangiopathyinfamilialbritishdanishandnonalzheimerʼsdementias
AT brinkmalmgunnar chemicaltraitsofcerebralamyloidangiopathyinfamilialbritishdanishandnonalzheimerʼsdementias
AT zetterberghenrik chemicaltraitsofcerebralamyloidangiopathyinfamilialbritishdanishandnonalzheimerʼsdementias
AT blennowkaj chemicaltraitsofcerebralamyloidangiopathyinfamilialbritishdanishandnonalzheimerʼsdementias
AT ryannatalies chemicaltraitsofcerebralamyloidangiopathyinfamilialbritishdanishandnonalzheimerʼsdementias
AT lashleytammaryn chemicaltraitsofcerebralamyloidangiopathyinfamilialbritishdanishandnonalzheimerʼsdementias
AT hanriederjorg chemicaltraitsofcerebralamyloidangiopathyinfamilialbritishdanishandnonalzheimerʼsdementias